Drug class

Glycoprotein IIB/IIIA Receptor Inhibitor

A glycoprotein IIb/IIIa receptor inhibitor is a class of intravenous antiplatelet medication designed to prevent arterial thrombus formation. Read more about Glycoprotein IIB/IIIA Receptor Inhibitor

19 drugs in this class 14 manufacturers

Advertisement

Drugs in Glycoprotein IIB/IIIA Receptor Inhibitor

Showing 1–9 of 19 drugs

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR · ACUTE CORONARY SYNDROME ·+1
ACCORD HEALTHCA

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR · ACUTE CORONARY SYNDROME ·+1
SAGENT PHARMACE

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR · ACUTE CORONARY SYNDROME ·+1
MYLAN INSTITUTI

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR · ACUTE CORONARY SYNDROME ·+1
Baxter Healthcare Company

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR · ACUTE CORONARY SYNDROME ·+1
SLATE RUN PHARM
Filter & compare in the drug finder → Opens the drug finder with Glycoprotein IIB/IIIA Receptor Inhibitor preselected. Add indication or manufacturer filters there.

About Glycoprotein IIB/IIIA Receptor Inhibitor.

A glycoprotein IIb/IIIa receptor inhibitor is a class of intravenous antiplatelet medication designed to prevent arterial thrombus formation.

These agents work by selectively binding to the platelet membrane glycoprotein IIb/IIIa integrin complex, blocking fibrinogen and von Willebrand factor from cross-linking adjacent platelets during the final common pathway of platelet aggregation.

Clinically, they are primarily utilized in acute cardiovascular care, specifically for managing acute coronary syndromes such as unstable angina and non-ST elevation myocardial infarction, and as adjunctive therapy to reduce ischemic complications during percutaneous coronary intervention.